Compare Cassava Sciences Inc (FLNA) vs TJX Companies Inc (TJX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs TJX Companies Inc — how do they compare? Cassava Sciences Inc trades at $1.1 (market cap $53.14M), while TJX Companies Inc trades at $151.21 (market cap $166.78B). The key difference: TJX Companies Inc is far larger — about 3138.5× Cassava Sciences Inc's market cap, and TJX Companies Inc pays a 1.27% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | TJX | |
|---|---|---|
Market Cap | $53.14M | $166.78B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $168.41 |
52-Week Low | $1.09 | $121.35 |
Enterprise Value | -$33.43M | $175.38B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
TJX Companies (TJX) trades at $154.81, up 2.97% today, with strong earnings beats in recent quarters. The stock shows a bullish fundamental profile with 9.4% net income margin and 61.25% ROE, though technical indicators signal near-term bearish pressure. Revenue growth accelerated to $56.36B in 2025, with analyst consensus strongly favoring Buy ratings (88.46%). Recent news highlights TJX as a defensive retail play during economic uncertainty, with expansion in international markets like Europe and Australia.
Outlook remains positive given consistent earnings outperformance and robust cash flow, but valuation multiples (P/E 29.37) suggest premium pricing. Key risks include consumer spending volatility and competitive pressures. Wall Street's average price target of $181.80 implies ~17% upside, supported by institutional confidence and dividend stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →
